个人中心 - 老虎社区

Jamesohl

IP属地：未知

帖子 · 4帖子 · 4
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- JamesohlJamesohl
  ·2021-06-17
  Wow
  非常抱歉，此主贴已删除
  1,085 评论
  点赞
  分享
  举报
- JamesohlJamesohl
  ·2021-03-29
  Wow
  Taiwan says no progress in BioNTech vaccine talks
  TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's BioNT
  Taiwan says no progress in BioNTech vaccine talks
  1,350 评论
  点赞
  分享
  举报
- JamesohlJamesohl
  ·2021-03-18
  Wow
  非常抱歉，此主贴已删除
  1,289 评论
  2
  分享
  举报
- JamesohlJamesohl
  ·2021-02-02
  Wow
  非常抱歉，此主贴已删除
  1,049 评论
  点赞
  分享
  举报
暂无关注

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574700658662797","uuid":"3574700658662797","gmtCreate":1611606635191,"gmtModify":1611973243672,"name":"Jamesohl","pinyin":"jamesohl","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/707adfde39b1d8b9102a0329a03899b2","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":52,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.02.06","exceedPercentage":"80.91%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.15","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":163854060,"gmtCreate":1623876275950,"gmtModify":1634026695812,"author":{"id":"3574700658662797","authorId":"3574700658662797","name":"Jamesohl","avatar":"https://static.tigerbbs.com/707adfde39b1d8b9102a0329a03899b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574700658662797","authorIdStr":"3574700658662797"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/163854060","repostId":"1118154026","repostType":4,"isVote":1,"tweetType":1,"viewCount":1085,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":352719738,"gmtCreate":1617003885724,"gmtModify":1634523196747,"author":{"id":"3574700658662797","authorId":"3574700658662797","name":"Jamesohl","avatar":"https://static.tigerbbs.com/707adfde39b1d8b9102a0329a03899b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574700658662797","authorIdStr":"3574700658662797"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/352719738","repostId":"2123235334","repostType":2,"repost":{"id":"2123235334","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1616999721,"share":"https://www.laohu8.com/m/news/2123235334?lang=&edition=full","pubTime":"2021-03-29 14:35","market":"us","language":"en","title":"Taiwan says no progress in BioNTech vaccine talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2123235334","media":"Reuters","summary":"TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's BioNT","content":"<html><body><p>TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    for its COVID-19 vaccine though talks are continuing, Taiwanese Health Minister Chen Shih-chung said on Monday.</p><p>   Taiwan complained last month that the firm had pulled out of a deal to sell it 5 million doses at the last minute, possibly due to Chinese pressure. BioNTech responded by saying it did plan on providing the vaccine. </p><p>   Speaking at parliament, Chen was downbeat on the chances for finalising the agreement.</p><p>   \"At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less,\" he added.</p><p>   Taiwan has a contract for five million of Moderna Inc's</p><p>  COVID-19 shot, a messenger RNA vaccine that relies on similar technology as that used by the Pfizer-BioNTech <a href=\"https://laohu8.com/S/AONE\">one</a>. </p><p>   Chen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a>, though Taiwan would still like them if possible.</p><p>   \"We are still in communication with them,\" he added. </p><p>   BioNTech did not immediately respond to a request for comment.    </p><p>   BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group Co Ltd    to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan. </p><p>   In return it agreed to pay up to $85 million in licensing fees and invest $50 million for a stake in the German firm.</p><p>   BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc   .</p><p>   Taiwan began its vaccination programme this month with AstraZeneca    shots. </p><p>   There are only 34 active cases being treated in hospital in Taiwan.</p><p> (Reporting by Ben Blanchard; Editing by Stephen Coates)</p><p>((ben.blanchard@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Taiwan says no progress in BioNTech vaccine talks</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTaiwan says no progress in BioNTech vaccine talks\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-03-29 14:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>    for its COVID-19 vaccine though talks are continuing, Taiwanese Health Minister Chen Shih-chung said on Monday.</p><p>   Taiwan complained last month that the firm had pulled out of a deal to sell it 5 million doses at the last minute, possibly due to Chinese pressure. BioNTech responded by saying it did plan on providing the vaccine. </p><p>   Speaking at parliament, Chen was downbeat on the chances for finalising the agreement.</p><p>   \"At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less,\" he added.</p><p>   Taiwan has a contract for five million of Moderna Inc's</p><p>  COVID-19 shot, a messenger RNA vaccine that relies on similar technology as that used by the Pfizer-BioNTech <a href=\"https://laohu8.com/S/AONE\">one</a>. </p><p>   Chen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the BioNTech <a href=\"https://laohu8.com/S/AONE.U\">one</a>, though Taiwan would still like them if possible.</p><p>   \"We are still in communication with them,\" he added. </p><p>   BioNTech did not immediately respond to a request for comment.    </p><p>   BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group Co Ltd    to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan. </p><p>   In return it agreed to pay up to $85 million in licensing fees and invest $50 million for a stake in the German firm.</p><p>   BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc   .</p><p>   Taiwan began its vaccination programme this month with AstraZeneca    shots. </p><p>   There are only 34 active cases being treated in hospital in Taiwan.</p><p> (Reporting by Ben Blanchard; Editing by Stephen Coates)</p><p>((ben.blanchard@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2123235334","content_text":"TAIPEI, March 29 (Reuters) - There has been no progress on talks to seal a deal with Germany's BioNTech SE    for its COVID-19 vaccine though talks are continuing, Taiwanese Health Minister Chen Shih-chung said on Monday.   Taiwan complained last month that the firm had pulled out of a deal to sell it 5 million doses at the last minute, possibly due to Chinese pressure. BioNTech responded by saying it did plan on providing the vaccine.    Speaking at parliament, Chen was downbeat on the chances for finalising the agreement.   \"At present there has been no further progress, and the opportunity for both to complete the contract is getting less and less,\" he added.   Taiwan has a contract for five million of Moderna Inc's  COVID-19 shot, a messenger RNA vaccine that relies on similar technology as that used by the Pfizer-BioNTech one.    Chen said that with the Moderna ones coming, as well as domestically made vaccines in development, there was less urgency to obtain the BioNTech one, though Taiwan would still like them if possible.   \"We are still in communication with them,\" he added.    BioNTech did not immediately respond to a request for comment.       BioNTech signed a deal with Chinese firm Shanghai Fosun Pharmaceutical Group Co Ltd    to exclusively develop and commercialise COVID-19 vaccine products developed using BioNTech's mRNA technology in mainland China, Hong Kong, Macau and Taiwan.    In return it agreed to pay up to $85 million in licensing fees and invest $50 million for a stake in the German firm.   BioNTech's development and distribution partner for the rest of the world is U.S. firm Pfizer Inc   .   Taiwan began its vaccination programme this month with AstraZeneca    shots.    There are only 34 active cases being treated in hospital in Taiwan. (Reporting by Ben Blanchard; Editing by Stephen Coates)((ben.blanchard@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":1350,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":327029169,"gmtCreate":1616040912651,"gmtModify":1703496763996,"author":{"id":"3574700658662797","authorId":"3574700658662797","name":"Jamesohl","avatar":"https://static.tigerbbs.com/707adfde39b1d8b9102a0329a03899b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574700658662797","authorIdStr":"3574700658662797"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/327029169","repostId":"2120136385","repostType":2,"isVote":1,"tweetType":1,"viewCount":1289,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":315204022,"gmtCreate":1612252920366,"gmtModify":1703759300479,"author":{"id":"3574700658662797","authorId":"3574700658662797","name":"Jamesohl","avatar":"https://static.tigerbbs.com/707adfde39b1d8b9102a0329a03899b2","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3574700658662797","authorIdStr":"3574700658662797"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/315204022","repostId":"1131925624","repostType":4,"isVote":1,"tweetType":1,"viewCount":1049,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"following","isTTM":false}